SGLT2 Inhibitors: From Structure-Effect Relationship to Pharmacological Response.

Area of Science:

• Pharmacology and Therapeutics
• Metabolic Diseases
• Cardiovascular and Renal Medicine

Background:

• Sodium-glucose cotransporter 2 (SGLT2) inhibitors are increasingly utilized for type 2 diabetes management.
• Their therapeutic applications extend to cardiovascular, renal, hepatic diseases, and obesity within metabolic syndrome.

Purpose of the Study:

• To review the mechanisms of action of SGLT2 inhibitors in metabolic syndrome and related conditions.
• To explore the structure-activity relationships of gliflozins and their impact on pharmacokinetic and pharmacodynamic properties.
• To discuss the potential for developing new therapeutic uses and mitigating adverse effects.

Main Methods:

• Review of existing literature on SGLT2 inhibitors, focusing on their chemical structure and biological effects.
• Analysis of how modifications to the carbohydrate, aglycone, and glycosidic bond influence drug properties.
• Examination of the impact on glucose metabolism, lipid metabolism, and inflammatory pathways.

Main Results:

• SGLT2 inhibitors improve glycemic control and positively affect lipid metabolism by promoting lipid mobilization and utilization.
• These agents exhibit anti-inflammatory properties by reducing pro-inflammatory mediators and modulating cell signaling.
• Structure-activity relationship analysis reveals how molecular modifications correlate with therapeutic outcomes.

Conclusions:

• SGLT2 inhibitors possess multifaceted therapeutic benefits for metabolic syndrome and associated diseases.
• Understanding gliflozin structure-effect relationships can guide the development of novel therapeutic applications.
• Further research is warranted to expand indications and address adverse effects, such as lower limb amputations.